跳至主要内容
临床试验/NCT04153253
NCT04153253已完成4 期

Intravitreal Aflibercept Injection With Panretinal Photocoagulation Versus Early Vitrectomy for Diabetic Vitreous Hemorrhage

Al Hadi Hospital1 个研究点 分布在 1 个国家目标入组 34 人开始时间: 2018年3月7日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
34
试验地点
1
主要终点
Mean best corrected visual acuity(BCVA) change in both groups.

研究概览

简要总结

Prospective study comparing efficacy and safety of intravitreal aflibercept injection and panretinal photocoagulation to early vitrectomy for patients with diabetic vitreous hemorrhage.

详细描述

Selected patients were divided into two groups, Group I for whom intravitreal aflibercept injection followed by panretinal photocoagulation was done and group II for whom early vitrectomy was done.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age above 18 years.
  • Type Ι or ΙΙ DM,
  • recent diabetic VH which is causing vision impairment, precluding complete PRP and needing treatment.
  • BCVA is less than 20/70 (log MAR BCVA 0.6) and better than 20/1000 (log MAR BCVA 1.7).

排除标准

  • Tractional retinal detachment.
  • Previous PRP.
  • History of anti VEGF therapy within the past two months.
  • Neovascular glaucoma
  • Subhyaloid hemorrhage.
  • Vitreomacular traction.
  • Diabetic macular edema .
  • Patients with systemic contraindications for anti VEGF or unstable medical conditions as uncontrolled hypertension (persistently above 180/110 mmhg) or recent thromboembolic event within the past six months.

研究组 & 干预措施

Group I

Active Comparator

Intravitreal injection of Aflibercept followed by panretinal photocoagulation.

干预措施: Aflibercept Injection [Eylea] (Drug)

Group II: Early vitrectomy.

Active Comparator

Early vitrectomy.

干预措施: Vitrectomy (Procedure)

结局指标

主要结局

Mean best corrected visual acuity(BCVA) change in both groups.

时间窗: 9 months follow up.

Final BCVA change measured in log MAR compared to initial BCVA.

次要结局

  • Rate of recurrent bleeding.(9 months follow up.)
  • Number of additional treatment procedures .(9 months follow up)

研究者

发起方
Al Hadi Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Abeer MohamedSadeck Khattab

Abeer Mohamed Sadeck Khattab ,associate professor of ophthalmology.

Al Hadi Hospital

研究点 (1)

Loading locations...

相似试验